PO-1217: Safety of Nivolumab and stereotactic RT in metastatic renal carcinoma: early results of NIVES study
Patrizia Ciammella(Azienda Sanitaria Unità Locale di Reggio Emilia), Cinzia Iotti(Azienda Sanitaria Unità Locale di Reggio Emilia), Francesco Salaroli(University of Parma), Carmine Pinto(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Renzo Mazzarotto, Alessio Bruni(University of Modena and Reggio Emilia), Cristina Masini(Ospedale Santa Maria), Riccardo Belli(Azienda Ospedaliero Universitaria San Giovanni Battista), Giorgia Timon(Azienda Sanitaria Unità Locale di Reggio Emilia)
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
|Modern Pathology|2015|317
Stereotactic body radiation therapy for early stage non-small cell lung cancer: Results of a prospective trial
|Lung Cancer|2009|277
Stereotactic body radiation therapy for lung metastases
|Lung Cancer|2011|146